Fenobam has anxiolytic effects comparable to those of [[benzodiazepine]] drugs,<ref name="pmid16040814"/><ref>{{cite journal | pmid = 7042771 | year = 1982 | last1 = Pecknold | first1 = JC | last2 = McClure | first2 = DJ | last3 = Appeltauer | first3 = L | last4 = Wrzesinski | first4 = L | last5 = Allan | first5 = T | title = Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study | volume = 2 | issue = 2 | pages = 129–33 | journal = Journal of Clinical Psychopharmacology | doi=10.1097/00004714-198204000-00010}}</ref><ref>{{cite journal | pmid = 6142427 | year = 1983 | last1 = Goldberg | first1 = ME | last2 = Salama | first2 = AI | last3 = Patel | first3 = JB | last4 = Malick | first4 = JB | title = Novel non-benzodiazepine anxiolytics | volume = 22 | issue = 12B | pages = 1499–504 | journal = Neuropharmacology | doi=10.1016/0028-3908(83)90118-1}}</ref> but was never commercially marketed for the treatment of anxiety due to dose-limiting side effects such as amnesia and psychotomimetic symptoms.<ref>{{cite journal | pmid = 17582504 | year = 2007 | last1 = Palucha | first1 = A | last2 = Pilc | first2 = A | title = Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs | volume = 115 | issue = 1 | pages = 116–47 | doi = 10.1016/j.pharmthera.2007.04.007 | journal = Pharmacology & therapeutics}}</ref><ref name="pmid19426746">{{cite journal |vauthors=Jacob W, Gravius A, Pietraszek M, Nagel J, Belozertseva I, Shekunova E, Malyshkin A, Greco S, Barberi C, Danysz W |title=The anxiolytic and analgesic properties of fenobam, a potent mGlu5 receptor antagonist, in relation to the impairment of learning |journal=Neuropharmacology |volume= 57|issue= 2|pages= 97–108|date=May 2009 |pmid=19426746 |doi=10.1016/j.neuropharm.2009.04.011 |url=}}</ref> Following the discovery of its activity as a potent negative allosteric modulator of mGluR<sub>5</sub>, fenobam has been re-investigated for many applications, with its profile of combined antidepressant, anxiolytic, analgesic and anti-addictive effects potentially useful given the common co-morbidity of these symptoms.<ref>{{cite journal | pmid = 18991960 | year = 2008 | last1 = Carroll | first1 = FI | title = Antagonists at metabotropic glutamate receptor subtype 5: Structure activity relationships and therapeutic potential for addiction | volume = 1141 | pages = 221–32 | doi = 10.1196/annals.1441.015 | journal = Annals of the New York Academy of Sciences}}</ref><ref name="pmid19515968">{{cite journal |vauthors=Montana MC, Cavallone LF, Stubbert KK, Stefanescu AD, Kharasch ED, Gereau RW |title=The mGlu5 antagonist fenobam is analgesic and has improved in vivo selectivity as compared to the prototypical antagonist MPEP |journal=The Journal of Pharmacology and Experimental Therapeutics |volume= 330|issue= 3|pages= 834–43|date=June 2009 |pmid=19515968 |doi=10.1124/jpet.109.154138 |url= |pmc=2729799}}</ref> It has also shown promising initial results in the treatment of [[fragile X syndrome]].<ref>{{cite journal | pmid = 19126569 | year = 2009 | last1 = Berry-Kravis | first1 = E | last2 = Hessl | first2 = D | last3 = Coffey | first3 = S | last4 = Hervey | first4 = C | last5 = Schneider | first5 = A | last6 = Yuhas | first6 = J | last7 = Hutchison | first7 = J | last8 = Snape | first8 = M | last9 = Tranfaglia | first9 = M | last10 = Nguyen | first10 = D V | last11 = Hagerman | first11 = R | title = A pilot open label, single dose trial of fenobam in adults with fragile X syndrome | volume = 46 | issue = 4 | pages = 266–71 | doi = 10.1136/jmg.2008.063701 | pmc = 2658751 | journal = Journal of Medical Genetics| display-authors = 8 }}</ref> It was developed by a team at McNeil Laboratories in the 1970s.<ref>US Patent 3983135 4-Oxo-2-imidazolidinylidene ureas</ref>
